A2 to O Lung Transplants

Status Recruiting

Clinical Trial Summary

Blood group A2 to blood group O kidney and liver transplants have been shown to be safe and successful, especially in recipients with low pre-operative anti-A antibody titers and with the use of peri-operative antibody-depleting therapies. Since blood group O lung transplant candidates tend to have longer wait times and a higher waitlist mortality compared to other blood groups, we propose to conduct a prospective study of lung transplantation from blood group A2 donors to eligible blood group O recipients in an effort to increase the available donor pool. The aim of this study is to determine both the feasibility and safety of this specific type of ABO-incompatible lung transplant, and the impact of this practice on reducing transplant wait times among blood group O lung transplant candidates. This would represent the first prospective study of ABO-incompatible lung transplants worldwide.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05581745
Study type	Interventional
Source	University Health Network, Toronto
Contact	Sharaniyaa Balachandran
Phone	416-340-4800
Email	sharaniyaa.balachandran@uhn.ca
Status	Recruiting
Phase	N/A
Start date	July 14, 2022
Completion date	December 31, 2032

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05404919` - Utilization of Hepatitis B Virus NAT+ Donors for Hepatitis B Vaccinated Lung Transplant Candidates	Phase 2
Completed	`NCT03299504` - Factors Predicting Success in Lung Transplant Recipients Who Have Undergone Intensive Post-operative Rehabilitation
Completed	`NCT00755781` - Study of Cyclosporine Inhalation Solution (CIS) in Improving Bronchiolitis Obliterans Syndrome-Free Survival Following Lung Transplantation	Phase 3
Recruiting	`NCT05547698` - A Study of Venoarterial ECMO vs Off-Pump Bilateral Orthotopic Lung Transplantation	N/A
Terminated	`NCT03207399` - Lung Transplantation in Chronic HCV Infection With Post Transplant EPCLUSA Treatment	Phase 4
Completed	`NCT03300882` - PREDICT Cytomegalovirus (CMV)
Recruiting	`NCT05101460` - An All Comers Registry For Normothermic Ex Vivo Lung Perfusion (EVLP) as Assessment of Donor Lungs for Transplant
Completed	`NCT03150095` - Health Coaching to Improve Self-Management in Thoracic Transplant Candidates	N/A
Completed	`NCT04420195` - Envarsus XR in Lung Transplant	Phase 2
Recruiting	`NCT02235610` - Use of Ex Vivo Lung Perfusion (EVLP) in Reconditioning Marginal Donor Lungs for Transplantation	N/A
Not yet recruiting	`NCT06066229` - Identification of Patient Important Outcomes in Lung Transplantation
Recruiting	`NCT04601818` - Planned Semi-Elective Lung Tx Study	N/A
Recruiting	`NCT03072589` - Study to Evaluate Adenosine 2A Receptor Agonist (Regadenoson) in Patients Undergoing Lung Transplantation	Phase 1
Completed	`NCT01963780` - International EXPAND Lung Pivotal Trial	N/A
Recruiting	`NCT05671887` - DREAM: Double Lung Transplant REgistry Aimed for Lung-limited Malignancies
Completed	`NCT03987113` - Impact of Cold Ischemia on Pulmonary Endothelial Dysfunction in Ex-vivo Pulmonary Reconditioning
Recruiting	`NCT02748798` - Developing Optimal Parameters for Hyperpolarized Noble Gas and Inert Fluorinated Gas MRI of Lung Disorders	Early Phase 1
Completed	`NCT03167528` - Contribution of Learning and Practice of Different Complementary Therapies in Pulmonary Transplant Patients	N/A
Active, not recruiting	`NCT04244734` - Implementation of an Early Rehabilitation Program for the Patient With Lung Transplantation: From the ICU to Home.	N/A
Active, not recruiting	`NCT01365429` - Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs	N/A